Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S MOTRIN versus LODINE XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S MOTRIN versus LODINE XL.
CHILDREN'S MOTRIN vs LODINE XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis leading to anti-inflammatory, analgesic, and antipyretic effects.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
400 mg or 600 mg orally once daily.
None Documented
None Documented
2-4 hours in children; prolonged in neonates and hepatic impairment.
Terminal elimination half-life is approximately 6-7 hours. Steady-state is achieved within 2 days.
Renal (90%) as inactive metabolites and conjugates; fecal (<5%).
Renal excretion of metabolites accounts for approximately 70% of a dose; fecal excretion accounts for about 20%.
Category C
Category C
NSAID
NSAID